Europe – CHMP backs approval of 13 new drugs for various diseases

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended 13 new medicines for approval in its latest meeting.

This includes AstraZeneca’s COVID-19 vaccine – the CHMP has recommended granting the jab a conditional marketing authorisation for use in people aged 18 years and older.

Novartis’ multiple sclerosis (MS) treatment Kesimpta (ofatumumab) received a positive opinion for the treatment of patients with active relapsing forms of MS.

Amarin’s heart failure drug Vazkepa (icosapent ethyl) was also handed a recommendation for a conditional marketing authorisation to reduce the risk of cardiovascular events in high risk patients.

The CHMP also recommended granting a conditional marketing authorisation for Karyopharm’s Nexpovio (selinexor) for the treatment of relapsed or refractory myeloma…